Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. PMCB
PMCB logo

PMCB

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

PMCB News

Autodesk Shares Rise Approximately 6%; 20 Stocks Making Moves in Premarket Trading

Nov 26 2025Benzinga

PharmaCyte Monetizes Femasys Stake, Boosts Cash to $20 Million

Nov 25 2025Newsfilter

PharmaCyte Biotech, Inc. Expands Investment in TNF Pharmaceuticals Following New License for Innovative Light Speed Computing Platform for Cryptocurrency Use

Sep 02 2025Newsfilter

PharmaCyte Biotech, Inc. Secures $7 Million in Funding from Current Investors

Aug 18 2025Newsfilter

PharmaCyte Biotech announces $7 million strategic investment in MYMD

May 21 2024SeekingAlpha

PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value

Oct 07 2022globenewswire

NT 10-K Form - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 - PharmaCyte Biotech, Inc. (0001157075) (Filer)

undefined NaN NaNNewsfilter

8-K Form - Current report, item 5.07 - PharmaCyte Biotech, Inc. (0001157075) (Filer)

undefined NaN NaNNewsfilter